PIN7 Qualitative Research Methods to Evaluate Healthcare Provider and Adult Vaccine Recipient Attitudes, Barriers, and Facilitators to Completing the Recombinant Zoster Vaccine Regimen in Canada

Abstract

The National Advisory on Canadian Immunizations recommends the two-dose recombinant zoster vaccine (RZV) for prevention of herpes zoster in adults ≥50 years old. Research shows only 65%–75% of vaccine recipients in Canada complete the RZV series, the reason for which is unclear. Literature on factors influencing multi-dose vaccine completion among adults is limited as most adult vaccines are single-dose. Qualitative research from the perspectives of healthcare providers (HCPs) and vaccine recipients can provide insights on multi-dose vaccine compliance and completion through the generation of rich and nuanced data. The qualitative research methodology that will be used to explore HCP and vaccine recipient attitudes, barriers, and facilitators related to completing the RZV regimen is described. Two rounds of one-on-one semi-structured concept elicitation (CE) interviews will be conducted via telephone/webcam. CE is commonly used in qualitative research to better understand a condition, disease, or treatment experience. The first round of interviews will involve up to 12 HCPs. The second will examine up to 40 healthy adults ≥50 years old, who have received ≥1 RZV doses. Concepts identified in HCP interviews will be incorporated into subsequent interviews with vaccine recipients. Sample size will be determined when saturation of concepts, i.e. the point at which no new concepts emerge from interviews, is reached. All interview transcripts will be coded and analyzed using a two-part thematic analysis approach incorporating both codes developed in advance and those developed and refined in an on-going manner as transcripts are reviewed and analyzed. This mix of coding methods will ensure aspects of interest are addressed while leaving room to consider new concepts, descriptions, and experiences. This qualitative study will yield insights that may help inform relevant stakeholders of novel approaches to improve RZV series completion to optimize protection against herpes zoster and offer a basis for future research.